Ontology highlight
ABSTRACT: Importance
In men with recurrent prostate cancer, addition of long-term antiandrogen therapy to salvage radiotherapy (SRT) was associated with overall survival (OS) in the NRG/RTOG 9601 study. However, hormone therapy has associated morbidity, and there are no validated predictive biomarkers to identify which patients derive most benefit from treatment.Objective
To examine the role of pre-SRT prostate-specific antigen (PSA) levels to personalize hormone therapy use with SRT.Interventions
Men were randomized to SRT plus high-dose nonsteroidal antiandrogen (bicalutamide, 150 mg/d) or placebo for 2 years.Design, setting, and participants
In this secondary analysis of the multicenter RTOG 9601 double-blind, placebo-controlled randomized clinical trial conducted
SUBMITTER: Dess RT
PROVIDER: S-EPMC7189892 | biostudies-literature | 2020 May
REPOSITORIES: biostudies-literature